A better payload doesn't solve the entire delivery problem.
After five years of doctoral research, twin sisters @ikeda_trashi and @OTrashi are building @biodelivera (YC F26) to tackle how therapies reach the right cells.
Their GCV platform is designed to deliver therapeutic payloads into selected cells, with the goal of making targeted drug delivery more effective.
fondo.ai/4jqfqwg
Building a startup after your PhD.
Recently, YC released a video about the mistakes academics make when building startups.
Here is my view and how we built @BioDelivera while being PhDs.
When I started my PhD, I was obsessed with making something that could improve people’s lives.
The amount of drugs that sit in the clinical trials just because they couldn’t reach the right cells is unbelievable ! Genetic medicine is the biggest promise in medicine and we can only unlock its full potential if we can get these therapies where they need to go.
We are launching a drug delivery platform to get therapies to the right place. 0.1-3% of the therapy a patients gets goes to disease the rest goes all over our body attacking healthy cells and making them so sick that they cant even take the treatment!
@ikeda_trashi@OTrashi
Today we are launching @BioDelivera a programmable drug delivery platform that delivers therapies only to diseased cells enabling cures for every disease. 🎯🧪
Less than 3% of an injected therapy reaches diseased cells. The rest ends up in healthy organs. At @BioDelivera we want to change that, our mission is to make every therapy accessible to patients.
Happy to build with @ikeda_trashi this exciting technology!
Reach out at founders@biodelivera.com
Me and my twin sister @ikeda_trashi, built @BioDelivera on the foundation of five years of PhD research to break the limits of drug delivery and enable cures for every disease. 💥
Today, less than 3% of injected therapy reaches diseased cells. Most of it spreads throughout the body, exposing healthy organs to drugs they don't need. Poor targeting causes toxicity, makes patients sick, and forces lower doses that limit how effective treatments can be.
We cherry-picked the finest elements and created Guided Chimeric Vehicles (GCVs). 🦠
These chimeric nanoparticles are specifically designed to bind to the desired cell with no off-target to healthy organs.
The platform is programmable to target cells across cancer, brain, muscles, and other hard-to-reach organs, including cells involved in age-related diseases.🚀
What is your biggest struggle you are facing right now in drug delivery?
Happy to pitch with @ikeda_trashii our platform technology for cancer treatment, and yes we won the 1st place in student track at @BigIdeaUTD YAY
So excited for BioDelivera and what we will bring to the world!
#biodelivera#bigideautd